What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received diverse analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 17.82% to $59.5. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Despite positive revenue growth, the company faces challenges with its net margin, ROE, and ROA compared to industry averages.
September 18, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rhythm Pharmaceuticals has received mostly bullish analyst ratings, with an increased average price target of $59.5. Despite positive revenue growth, the company faces challenges in net margin, ROE, and ROA compared to industry averages.
The majority of analysts have given bullish ratings, and the average price target has increased significantly, indicating positive sentiment. However, financial metrics like net margin, ROE, and ROA are below industry averages, which could temper the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100